Document Detail


Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs.
MedLine Citation:
PMID:  17116678     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A number of anticancer and antiparasitic drugs are postulated to target the polyamine biosynthetic pathway and polyamine function, but the exact mode of action of these compounds is still being elucidated. To establish whether polyamine analogs specifically target enzymes of the polyamine pathway, a model was developed using strains of the protozoan parasite Leishmania donovani that overproduce each of the polyamine biosynthetic enzymes. Promastigotes overexpressing episomal constructs encoding ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (ADOMETDC), or spermidine synthase (SPDSYN) revealed robust overproduction of the corresponding polyamine biosynthetic enzyme. Polyamine pools, however, were either unchanged or only marginally affected, implying that regulatory mechanisms must exist. The ODC, ADOMETDC, and SPDSYN overproducer strains exhibited a high level of resistance to difluoromethylornithine, 5'-{[(Z)-4-amino-2-butenyl]methylamino}-5'-deoxyadenosine, and n-butylamine, respectively, confirming previous observations that these agents specifically target polyamine enzymes. Conversely, augmented levels of polyamine biosynthetic enzymes did not affect the sensitivity of L. donovani promastigotes to pentamidine, berenil, and mitoguazone, drugs that were postulated to target the polyamine pathway, implying alternative and/or additional targets for these agents. The sensitivities of wild-type and overproducing parasites to a variety of polyamine analogs were also tested. The polyamine enzyme-overproducing lines offer a rapid cell-based screen for assessing whether synthetic polyamine analogs exert their mechanism of action predominantly on the polyamine biosynthetic pathway in L. donovani. Furthermore, the drug resistance engendered by the amplification of target genes and the overproduction of the encoded protein offers a general strategy for evaluating and developing therapeutic agents that target specific proteins in Leishmania.
Authors:
Sigrid C Roberts; Yuqui Jiang; Judith Gasteier; Benjamin Frydman; Laurence J Marton; Olle Heby; Buddy Ullman
Related Documents :
12597028 - Changes in free polyamines and related enzymes during stipule and pod wall development ...
21876378 - Cloning, expression, and characterization of a new xylanase from alkalophilic paenibaci...
3345508 - Induction of ornithine decarboxylase and histidine decarboxylase activities in rat colo...
11300698 - A reexamination of the substrate utilization of 2-thioorotidine-5'-monophosphate by yea...
9255588 - Chemoprevention by inducers of carcinogen detoxication enzymes.
12060258 - Purification and characterization of the raffinose oligosaccharide chain elongation enz...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-11-20
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  51     ISSN:  0066-4804     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-22     Completed Date:  2007-06-04     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  438-45     Citation Subset:  IM    
Affiliation:
Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239-3098, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosylmethionine Decarboxylase / biosynthesis*,  genetics
Animals
Antiprotozoal Agents / pharmacology*
Butylamines / pharmacology
Deoxyadenosines / pharmacology
Drug Resistance / genetics
Eflornithine / pharmacology
Leishmania donovani / drug effects*,  enzymology*,  genetics
Ornithine Decarboxylase / biosynthesis*,  genetics
Parasitic Sensitivity Tests / methods
Signal Transduction / drug effects
Spermidine Synthase / biosynthesis*,  genetics
Transfection
Grant Support
ID/Acronym/Agency:
AI10096/AI/NIAID NIH HHS; AI41622/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 0/Butylamines; 0/Deoxyadenosines; 123642-27-3/MDL 73811; 70052-12-9/Eflornithine; EC 2.5.1.16/Spermidine Synthase; EC 4.1.1.17/Ornithine Decarboxylase; EC 4.1.1.50/Adenosylmethionine Decarboxylase; N2QV60B4WR/n-butylamine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant ...
Next Document:  The relationship between quinolone exposures and resistance amplification is characterized by an inv...